"Chemokine CXCL1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine with specificity for CXCR2 RECEPTORS. It has growth factor activities and is implicated as a oncogenic factor in several tumor types.
| Descriptor ID |
D054360
|
| MeSH Number(s) |
D12.644.276.374.200.120.050 D12.776.467.374.200.120.050 D12.776.624.664.700.049 D23.125.300.120.050 D23.469.200.120.050 D23.529.374.200.120.050
|
| Concept/Terms |
Chemokine CXCL1- Chemokine CXCL1
- CXCL1, Chemokine
- CXCL1 Chemokine
- Chemokine, CXCL1
- Gro-alpha Protein
- Gro alpha Protein
- GROalpha Protein
- Melanoma Growth Stimulatory Activity, alpha Protein
- MGSA-alpha Chemokine
- Chemokine, MGSA-alpha
- MGSA alpha Chemokine
- Neutrophil-Activating Protein 3
- Neutrophil Activating Protein 3
- Chemokine (C-X-C Motif) Ligand 1
- Growth-Related Oncogene alpha Protein
- Growth Related Oncogene alpha Protein
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL1".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL1".
This graph shows the total number of publications written about "Chemokine CXCL1" by people in this website by year, and whether "Chemokine CXCL1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 2 | 2 |
| 2002 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 2 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL1" by people in Profiles.
-
LIFR regulates cholesterol-driven bidirectional hepatocyte-neutrophil cross-talk to promote liver regeneration. Nat Metab. 2024 Sep; 6(9):1756-1774.
-
Targeting ESE3/EHF With Nifurtimox Inhibits CXCR2+ Neutrophil Infiltration and Overcomes Pancreatic Cancer Resistance to Chemotherapy and Immunotherapy. Gastroenterology. 2024 Jul; 167(2):281-297.
-
CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma. J Hepatol. 2024 Jul; 81(1):93-107.
-
Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. 2021 01; 7(5).
-
PPARD and Interferon Gamma Promote Transformation of Gastric Progenitor Cells and Tumorigenesis in Mice. Gastroenterology. 2019 07; 157(1):163-178.
-
Reduced Corneal Innervation in the CD25 Null Model of Sj?gren Syndrome. Int J Mol Sci. 2018 Nov 30; 19(12).
-
Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):698-707.
-
Interleukin 35 Expression Correlates With Microvessel Density in?Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice. Gastroenterology. 2018 02; 154(3):675-688.
-
Molecular cloning and biophysical characterization of CXCL3 chemokine. Int J Biol Macromol. 2018 Feb; 107(Pt A):575-584.
-
Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Dec; 166(3):819-832.